Home » Open Orphan (ORPH) » Proactive Investors – Open Orphan #ORPH catching global attention with ‘stunning’ FLU-v results & world-first coronavirus study

Proactive Investors – Open Orphan #ORPH catching global attention with ‘stunning’ FLU-v results & world-first coronavirus study

Open Orphan PLC‘s (LON:ORPH) Cathal Friel and its subsidiary hVIVO’s chief scientist Dr Andrew Catchpole sat down with Proactive London’s Andrew Scott.

This morning Open Orphan announced the results from a clinical trial of a broad-spectrum flu jab that they’re jointly developing have been published in a peer-reviewed journal.

The data from the FLU-v 003 phase IIb study of the FLU-v vaccine appeared in the Annals of Internal Medicine periodical.

Also this week hVIVO began developing the world’s first human coronavirus challenge study.

hVIVO owns Europe’s only quarantine clinic with an onsite virology lab where the challenge model will be developed and used.


Leave a comment

I would like to receive Brand Communications updates and news...
Free Stock Updates & News
I agree to have my personal information transfered to MailChimp ( more information )
Join over 3.000 visitors who are receiving our newsletter and learn how to optimize your blog for search engines, find free traffic, and monetize your website.
We hate spam. Your email address will not be sold or shared with anyone else.